mRNA-based vaccine technology development

CureVac is accelerating vaccine technology development, getting lifesaving and low-cost vaccines to people who need them most.
  • Domain
  • Investment type
    Direct equity
  • Status
    Active
  • Initial investment
    Series F
  • Partnered in
    2015
  • Investment lead
    David Rossow
  • Headquarters
    Germany
  • Program strategy
    Vaccine Development

More about our work

Our focus

Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.

Investment approach

Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.

Our team

We bring depth of experience to every investment, with a proven track record across sectors and scale.